loading

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
04:58 AM

(KYMR) Trading Report - Stock Traders Daily

04:58 AM
pulisher
Nov 22, 2024

Jennison Associates LLC Purchases 368,394 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Nov 22, 2024
pulisher
Nov 20, 2024

Stephens Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Nov 20, 2024
pulisher
Nov 18, 2024

Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Stephens - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

US Bancorp DE Sells 651 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Stephens & Co. Initiates Coverage of Kymera Therapeutics (KYMR) with Overweight Recommendation - MSN

Nov 18, 2024
pulisher
Nov 15, 2024

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7%Here's What Happened - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Expands Stake in Kymera Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Long Term Trading Analysis for (KYMR) - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Bolsters Stake in Kymera Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $51.21 Average Price Target from Analysts - Defense World

Nov 12, 2024
pulisher
Nov 10, 2024

Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00 at Morgan Stanley - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $51.21 - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition in Kymer - GuruFocus.com

Nov 08, 2024
pulisher
Nov 05, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 05, 2024
pulisher
Nov 05, 2024

Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Kymera Therapeutics to Present at 5 Major Healthcare Investor Conferences in November | KYMR Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Nov 05, 2024
pulisher
Nov 04, 2024

UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Immunology to take front seat at Kymera - The Pharma Letter

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings call: Kymera Therapeutics advances in immunology and oncology By Investing.com - Investing.com Australia

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings call: Kymera Therapeutics advances in immunology and oncology - Investing.com India

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St

Nov 04, 2024
pulisher
Nov 04, 2024

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

(KYMR) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024
pulisher
Nov 02, 2024

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Guggenheim Increases Kymera Therapeutics (NASDAQ:KYMR) Price Target to $52.00 - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

The Latest Analyst Ratings For Kymera Therapeutics - Benzinga

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK

Nov 01, 2024
pulisher
Nov 01, 2024

B.Riley boosts Kymera stock target amid cautious optimism for STAT6 degrader - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics stock target lifted by Stifel, buy rating on oncology pivot - Investing.com UK

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap DownWhat's Next? - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics (KYMR) Q3 2024 Earnings: EPS Misses at -$0.8 - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To K - GuruFocus.com

Oct 31, 2024
pulisher
Oct 30, 2024

Preview: Kymera Therapeutics's Earnings - Benzinga

Oct 30, 2024
pulisher
Oct 30, 2024

Insights Ahead: Kymera Therapeutics's Quarterly Earnings - Benzinga

Oct 30, 2024
pulisher
Oct 24, 2024

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN

Oct 24, 2024
pulisher
Oct 24, 2024

Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases - StockTitan

Oct 24, 2024
pulisher
Oct 23, 2024

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 - ForexTV.com

Oct 23, 2024
pulisher
Oct 23, 2024

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium - The Manila Times

Oct 23, 2024
pulisher
Oct 17, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Kymera Therapeutics (NASDAQ:KYMR) Trading 6.8% HigherStill a Buy? - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decline in Short Interest - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 15, 2024
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
大文字化:     |  ボリューム (24 時間):